A Study to Evaluate the Safety of HS-10506 in Chinese Patients With Insomnia Disorder

Summary

The primary purpose of this open-label phase Ⅲ study is to evaluate the safety of HS-10506 on the incidence and severity of adverse events (AE), serious adverse events (SAE), adverse events of special interest (AESI) in Chinese adult participants with insomnia disorder.

Timeline

Start

2026-06-12

Primary completion

2029-06-30

Completion

2029-06-30

Drugs

Indications